PPAR? Variant Influences Angiographic Outcome and 10-Year Cardiovascular Risk in Male Symptomatic Coronary Artery Disease Patients  

Oleh:

Regieli, Jakub J. ; Jukema, J. Wouter ; Doevendans, Pieter A. ; Zwinderman, Aeilko H. ; Graaf, Yolanda van der

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Diabetes Care vol. 32 no. 05 (May 2009), page 839.

Ketersediaan

Perpustakaan FK Nomor Panggil: D05.K.2009.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

OBJECTIVE Activation of peroxisome proliferator–activated receptor (PPAR)-? signaling influences metabolic profiles and the propensity toward inflammation. Small-molecule stimulation of PPAR? is investigated for secondary prevention of cardiovascular disease. The common PPAR? Pro12Ala variant has functional and prognostic consequences. A protective effect of the 12Ala-allele carriership on diabetes and myocardial infarction in healthy populations has been suggested. The relevance of this pathway also needs exploration in patients with manifest vascular disease. We investigated the effects of carriership of the Pro12Ala variant on angiographic and cardiovascular event outcomes in male patients with symptomatic coronary artery disease (CAD). RESEARCH DESIGN AND METHODS The Regression Growth Evaluation Statin Study (REGRESS) cohort was genotyped for the Pro12Ala variant (rs1801282). Ten-year follow-up was derived from nation-wide registries, and risks were estimated using proportional hazards. Quantitative coronary angiography measurements were obtained and relations with genotype estimated using a generalized linear model. RESULTS Genotypes ascertained (n = 679) comprised 540 (80%) Pro/Pro, 126 (19%) Pro/Ala, and 13 (2%) Ala/Ala subjects. The 12Ala allele was associated with less extensive focal (P = 0.001) and diffuse (P = 0.002) atherosclerosis and lower 10-year cardiovascular risk. Hazard ratios were 0.10 (95% CI 0.01–0.70, P = 0.02) for ischemic heart disease and 0.24 (0.08–0.74, P = 0.013) for vascular death, per each added copy of 12Ala, respectively. CONCLUSIONS Carriers of the 12Ala allele of PPAR? have less widespread CAD and are considerably protected against 10-year (cardio)vascular morbidity and mortality. These long-term findings in patients with manifest CAD support an important role of PPAR? in determining vascular risk.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali